Optomed PLC (OPTOMED) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Optomed PLC (OPTOMED) has a cash flow conversion efficiency ratio of -0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.04 Million ≈ $-1.22 Million USD) by net assets (€20.24 Million ≈ $23.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Optomed PLC - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Optomed PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OPTOMED liabilities breakdown for a breakdown of total debt and financial obligations.
Optomed PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Optomed PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nsys Co. Ltd.
KQ:333620
|
0.014x |
|
GeneOne Life Science Inc
KO:011000
|
-0.065x |
|
Broad Capital Acquisition Corp Unit
NASDAQ:BRACU
|
0.008x |
|
Brand Group (M.G) Ltd
TA:BRND
|
0.030x |
|
Springwater Special Situations Corp
NASDAQ:SWSS
|
-0.007x |
|
Selic Corp Public Company Limited
BK:SELIC
|
0.030x |
|
Bluemount Holdings Limited Class B Ordinary Shares
NASDAQ:BMHL
|
-0.105x |
|
Enegex Ltd
AU:ENX
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Optomed PLC (2016–2024)
The table below shows the annual cash flow conversion efficiency of Optomed PLC from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Optomed PLC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €23.64 Million ≈ $27.63 Million |
€-1.60 Million ≈ $-1.87 Million |
-0.068x | -123.54% |
| 2023-12-31 | €20.36 Million ≈ $23.80 Million |
€-615.00K ≈ $-719.00K |
-0.030x | +74.07% |
| 2022-12-31 | €20.34 Million ≈ $23.78 Million |
€-2.37 Million ≈ $-2.77 Million |
-0.117x | +32.43% |
| 2021-12-31 | €17.05 Million ≈ $19.94 Million |
€-2.94 Million ≈ $-3.44 Million |
-0.172x | -23.56% |
| 2020-12-31 | €20.07 Million ≈ $23.47 Million |
€-2.80 Million ≈ $-3.27 Million |
-0.140x | -2062.15% |
| 2019-12-31 | €22.64 Million ≈ $26.47 Million |
€161.00K ≈ $188.23K |
0.007x | +151.96% |
| 2018-12-31 | €5.55 Million ≈ $6.49 Million |
€-76.00K ≈ $-88.85K |
-0.014x | +97.92% |
| 2017-12-31 | €1.16 Million ≈ $1.36 Million |
€-766.00K ≈ $-895.53K |
-0.659x | -186.47% |
| 2016-12-31 | €3.52 Million ≈ $4.12 Million |
€-810.00K ≈ $-946.98K |
-0.230x | -- |
About Optomed PLC
Optomed Oyj, together with its subsidiaries, manufactures and sells handheld fundus cameras in Finland, rest of Europe, and internationally. The company operates in two segments, Devices and Software. It develops, manufactures, and sells fundus cameras for ophthalmologists, pediatricians, endocrinologists, neurologists, and primary health care professionals; and provides professional IT consultin… Read more